In a nutshell This study evaluated the outcomes of autologous stem cell transplantation (ASCT) for patients with recurrent multiple myeloma (MM). This study found that long-term outcomes for these patients were promising, especially for patients who had the transplant right away after a first relapse. Some background Multiple myeloma (MM) is a type of...
Read More
In a nutshell This trial was carried out to compare bortezomib (Velcade; V) and carfilzomib (Kyprolis; K) in combination with Cd (cyclophosphamide and dexamethasone) as second line treatment in patients with relapsed multiple myeloma (MM). The authors found the KCd is as effective as VCd and K can also be used as a maintenance treatment in these...
Read More
In a nutshell This study aimed to investigate the effectiveness of DPd (daratumumab, pomalidomide, and dexamethasone) as salvage therapy followed by high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for relapsed/refractory (RR) multiple myeloma (MM). The study concluded that this therapy is effective and well tolerated...
Read More
In a nutshell This study examined if subcutaneous (sc) injections of daratumumab (Darzalex) were as effective and safe as intravenous (iv) infusions for patients with relapsed or refractory multiple myeloma (MM). The authors found that sc injections were as effective as iv infusions and caused fewer side effects. Some background Daratumumab...
Read MoreIn a nutshell The study compared the use of lenalidomide (Revlimid) and dexamethasone (Decadron) alone and with daratumumab (Darzalex) in patients with relapsed or unresponsive multiple myeloma (MM). The study showed that patients receiving all three drugs had better treatment response and survival. Some background MM is a type of cancer that affects...
Read More
In a nutshell This article provides recommendations for the treatment of multiple myeloma (MM). Some background MM is a type of blood cancer characterized by abnormal plasma cells. Plasma cells are a type of immune cell that antibodies to fight bacteria and viruses and stop infection and disease. In MM, abnormal plasma cells build up in the...
Read More
In a nutshell This study examined if PBD (pomalidomide, bortezomib, dexamethasone) was safe and effective in patients with multiple myeloma after lenalidomide (Revlimid) treatment. The authors concluded that pomalidomide improved survival without tumor growth or spread but increased side effects. Some background...
Read MoreIn a nutshell This study examined the safety and effectiveness of stem cell transplantation (SCT) in elderly patients with multiple myeloma (MM) aged 65 or older compared to younger patients. The authors concluded that SCT was equally as safe and effective for patients in both age groups. Some background Multiple myeloma is a complex type of...
Read More
In a nutshell This study evaluated the outcomes of patients with recurrent multiple myeloma (MM) after a stem cell transplant (SCT). This study concluded that these patients had a lower quality of life up to 2 years after treatment. Some background Multiple myeloma is a type of cancer of the bone marrow that can lead to abnormal immune cells. For...
Read MoreIn a nutshell This study will investigate the effects of a new treatment, GSK2857916, in patients with multiple myeloma (MM). Overall response will be the main outcome measured. The details There are many treatment options for MM. However, some patients do not respond to treatments or relapse. New therapies are being developed for these patients....
Read More
In a nutshell This study evaluated the impact of carfilzomib (Kyprolis) and dexamethasone (Decadron) on quality of life for patients with relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study concluded that patients treated with this combination had a higher quality of life. Some background MM is a...
Read MoreIn a nutshell This trial will investigate the effects of bb2121 in patients with non-responsive multiple myeloma (MM) who have progressed after standard treatment. The percentage of patients who respond and the percentage of patients who respond completely will be the main measures in this study. This study will take place in the United States and...
Read More
